title: Increased survival and reduced renal injury in MRL/lpr mice treated with a human Fcγ receptor II (CD32) peptide.
abstract: Systemic lupus erythematosus (SLE) is a multisystem chronic inflammatory disease affecting many organs. The deposition in kidney tissue of immune complexes and their interaction with macrophages is thought to trigger the inflammatory response leading to glomerulonephritis. It has been demonstrated that inhibition of this interaction in murine models can alleviate the disease. Six synthetic peptides were derived from the membrane-proximal extracellular domain (EC2) of human Fcγ receptor II (huFcγRII). Of these, one peptide, huRII6, was shown to be a potent competitive inhibitor of IgG binding to recombinant FcγRII in vitro. To examine the possible therapeutic impact of huRII6 in vivo, this peptide, or a control, was given by subcutaneous injection to female MRL/lpr mice from weeks 7 to 36, resulting in an enhanced survival rate compared with control-treated animals and a reduction of proteinuria. Histopathological examination of the kidneys showed a reduction in deposition of immune complexes and preservation of structure. Such a functional peptide should prove useful for examining the role of IgG-FcγR interactions in experimental models of disease and may provide for the development of FcR-targeting drugs to treat autoimmune disorders.
authors.affiliation: School of Food Science and Technology, Henan University of Technology, Zhengzhou, China. xijunhnu@yahoo.com.cn
authors.forename: Jun
authors.initials: J
authors.lastname: Xi
authors.forename: Gai P
authors.initials: GP
authors.lastname: Zhang
authors.forename: Song L
authors.initials: SL
authors.lastname: Qiao
authors.forename: Jun Q
authors.initials: JQ
authors.lastname: Guo
authors.forename: Xuan N
authors.initials: XN
authors.lastname: Wang
authors.forename: Yan Y
authors.initials: YY
authors.lastname: Yang
authors.forename: Li N
authors.initials: LN
authors.lastname: Zhang
authors.forename: Xian W
authors.initials: XW
authors.lastname: Miao
authors.forename: Dong
authors.initials: D
authors.lastname: Zhao
authors.forename: Yu B
authors.initials: YB
authors.lastname: Zhi
authors.forename: Shu J
authors.initials: SJ
authors.lastname: Cai
authors.forename: Jun
authors.initials: J
authors.lastname: Luo
authors.forename: Rui G
authors.initials: RG
authors.lastname: Deng
mesh_terms: D000818:Animals; D019556:COS Cells; D002522:Chlorocebus aethiops; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007668:Kidney / Q000293:injuries* / Q000473:pathology; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D051379:Mice; D019463:Mice, Inbred MRL lpr; D010446:Peptide Fragments / Q000276:immunology*; D017452:Receptors, IgG / Q000276:immunology* / Q000627:therapeutic use
chemical_list: D007074:Immunoglobulin G; D010446:Peptide Fragments; D017452:Receptors, IgG